Fortunately, most diabetes therapies, including metformin, thiazolidinediones, and dipeptidyl peptidase-4 inhibitors, have been shown to have a neutral or favorable effect on arrhythmia risk [23,24,25]. This evidence concerns the gene DPP4 and diabetes mellitus.